Recognition of the importance of the ER, PgR and the HER2 in BC, and the large scale use of immunohistochemistry (IHC), enabled almost every cancer centre in the world to differentiate BC patients into three major groups: the hormone receptor (HR) positive group (which expresses ER and/or PgR), the HER2 positive group (which expresses HER2 by IHC or amplification detected by fluorescence in situ hybridization (FISH) and the triple negative (TN, or basal-like tumors) group (which is negative for ER, PgR, and HER2). This evidence concerns the gene ERBB2 and breast cancer.